F S&P 500
5,522.50 +5.50 (+0.10%) F Dow Jones
39,895.00 +51.00 (+0.13%) F Nasdaq
19,794.75 +44.00 (+0.22%) E-mini Russell 2000 Index Futur
2,057.30 +4.50 (+0.22%) Petróleo
81.67 +0.04 (+0.05%) Oro
2,336.40 -8.00 (-0.34%)
Samsung Biologics Co.,Ltd. (207940.KS)
Samsung Biologics Co.,Ltd.
300, Songdobio-daero
Yeonsu-gu
Incheon 21987
South Korea
82 3 2455 3114
https://samsungbiologics.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo:
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. John Chongbo Rim | CEO, President & Chairman of Board | 3.12B | N/D | 1961 |
| Mr. Dong-Joong Kim | CFO, Executive VP, MD & Director | 666M | N/D | 1965 |
| Mr. Pierre Catignol | Executive VP & Head of Operation Center | N/D | N/D | 1968 |
| Dr. Namjin Chung Ph.D. | Executive VP and Head of Bio R&D Centre & CSO | N/D | N/D | N/D |
| Mr. James J. Choi | Executive VP, Head of CDO Development Center & Head of Sales Center | 569M | N/D | 1967 |
| Mr. Kyuho Lee | Executive VP, Head of People Center, & Chief Human Resource Officer | N/D | N/D | N/D |
| Dr. Brian Hosung Min Ph.D. | Executive VP & Head of CDO Development Center | N/D | N/D | N/D |
| Mr. Doyoung Heo | Vice President & Head of Finance | N/D | N/D | 1975 |
| Mr. Heekyun Lim | VP & Head of Business Consulting Team | N/D | N/D | 1975 |
| Dr. Kun Lo Ph.D. | Executive VP, Head of EPCV Center & Director | N/D | N/D | 1963 |
Descripción
Samsung Biologics Co.,Ltd. engages in the contract development and manufacturing organization (CDMO) business for biopharmaceuticals products in South Korea, Europe, the United States, and internationally. The company operates in two segments, CDMO, and Biopharmaceutical Development and Commercialization. Its development services include discovery, cell line development, process development, and clinical manufacturing. The company also offers aseptic filling, lyophilization, finishing, storage and shipping, and support services; and quality assurance and control, as well as biosafety and analytical testing services. In addition, it engages in the research and commercialization of biosimilar drugs; development and manufacture of antibody-drug conjugates; and manufactures mammalian and mRNA products. The company was founded in 2011 and is headquartered in Incheon, South Korea.
Gestión corporativa
La calificación ISS Governance QuickScore de Samsung Biologics Co.,Ltd. a partir del 1 de junio de 2024 es 5. Las puntuaciones principales son Auditoría: 1; Junta: 5; Derechos del accionista: 4; Compensación: 7.
